Novo Nordisk’s CagriSema Delivers 14.2% Weight Loss and 1.91% HbA1c Drop
Novo Nordisk reported that its combination drug CagriSema achieved 14.2% weight loss versus 10.2% with semaglutide and reduced HbA1c by 1.91%-points versus 1.76%-points in type 2 diabetes patients. The drug, submitted to the FDA in December 2025, showed a safe, well-tolerated profile with mainly mild gastrointestinal side effects.
1. Phase 3 Trial Delivers Breakthrough Results
Novo Nordisk reported headline data from the REIMAGINE 2 trial evaluating CagriSema, a fixed-dose combination of cagrilintide and semaglutide, in 2,728 adults with type 2 diabetes poorly controlled on metformin with or without an SGLT2 inhibitor. Over 68 weeks, the highest dose cohort (2.4 mg/2.4 mg) achieved an average weight reduction of 14.2% versus 10.2% for semaglutide alone, and an HbA1c drop of 1.91 percentage-points compared with 1.76 percentage-points. No weight-loss plateau was observed, suggesting continued efficacy beyond the trial’s duration.
2. Robust Efficacy Across Populations
Participants entered the study with a mean baseline weight of 101 kg and HbA1c of 8.2%. In the efficacy estimand analysis, 43% of those on CagriSema 2.4 mg/2.4 mg achieved at least 15% weight loss and 24% reached 20% or more. An alternative estimand showed a 12.9% mean weight reduction and a 1.80 percentage-point HbA1c decline when accounting for adherence, both outperforming semaglutide’s respective 9.2% and 1.68 percentage-points under the same conditions.
3. Safety Profile Supports Broad Use
CagriSema’s safety data revealed predominantly mild to moderate gastrointestinal events—nausea, vomiting and diarrhea—that diminished over time. Incidence and severity mirrored expectations for GLP-1 and amylin therapies, with no new safety signals. This tolerability profile underpins Novo Nordisk’s confidence in deploying the combination therapy for both obesity and type 2 diabetes populations, especially given the absence of serious adverse events or discontinuation rates above those seen with monotherapy.
4. Regulatory Milestones and Investor Implications
The U.S. FDA submission for CagriSema in weight management was filed in December 2025 on the back of positive REDEFINE data. With these REIMAGINE 2 results, Novo Nordisk will engage global regulators to expand indications into type 2 diabetes. Successful approvals could reinforce the company’s leadership in metabolic disease, countering recent competitive pressures and supporting long-term revenue growth projections. Investors will closely watch upcoming advisory committee decisions and readouts from trials comparing CagriSema to other leading agents.